Full View

Histone‐lysine N‐methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc‐driven liver cancer

DKH Thng, L Hooi, CCM Toh, JJ Lim… - Molecular …, 2023 - Wiley Online Library
Hepatocellular carcinoma (HCC) is the third deadliest and sixth most common cancer in the
world. Histone‐lysine N‐methyltransferase EHMT2 (also known as G9a) is a histone …
被引用次数：7 相关文章

Histone-lysine N-methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc-driven liver cancer

DKH Thng, L Hooi, CCM Toh, JJ Lim… - Molecular …, 2023 - pubmed.ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the third deadliest and sixth most common cancer in the
world. Histone-lysine N-methyltransferase EHMT2 (also known as G9a) is a histone …

Histone-lysine N-methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc-driven liver cancer

DKH Thng, L Hooi, CCM Toh, JJ Lim… - Molecular …, 2023 - search.proquest.com
Hepatocellular carcinoma (HCC) is the third deadliest and sixth most common cancer in the
world. Histone-lysine N-methyltransferase EHMT2 (also known as G9a) is a histone …

Histone-lysine N-methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc-driven liver cancer.

DKH Thng, L Hooi, CCM Toh, JJ Lim… - Molecular …, 2023 - europepmc.org
Hepatocellular carcinoma (HCC) is the third deadliest and sixth most common cancer in the
world. Histone-lysine N-methyltransferase EHMT2 (also known as G9a) is a histone …
[HTML] nih.gov

[HTML][HTML] Histone‐lysine N‐methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc‐driven liver cancer

DKH Thng, L Hooi, CCM Toh, JJ Lim… - Molecular …, 2023 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the third deadliest and sixth most common cancer in the
world. Histone‐lysine N‐methyltransferase EHMT2 (also known as G9a) is a histone …

[引用][C] Histone-lysine N-methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc-driven liver cancer

DKH Thng, L Hooi, CCM Toh, JJ Lim… - Molecular …, 2023 - europepmc.org
Liver cancer is the third most common cause of cancer-related death in the world with the
highest incidence in Asia. Current treatments for HCC include surgical resection, liver …